A summary of the key hepatitis C studies at the 21st Conference on Retroviruses and Opportunistic Infections in Boston.
10 March 2014 | BETA blog
HIV-positive men who have sex with men (MSM) who had a broad HIV transmission bottleneck were more likely to become infected with hepatitis C virus (HCV) during follow-up, according to results of a 558-man analysis in the Swiss HIV Cohort Study (SHCS).
06 March 2014 | NATAP
Combination of ledipasvir and sofosbuvir to be used in patients in urgent need of therapy to prevent progression of liver disease.
21 February 2014 | European Medicines Agency
HIV positive people with hepatitis C coinfection who start combination antiretroviral therapy (ART) are less likely to develop decompensated liver disease, or liver failure, according to a study published in the March 1, 2014, edition of Clinical Infectious Diseases.
21 February 2014 | HIVandHepatitis.com
Gilead’s new drug, Sovaldi, costs $84,000 for a 12-week treatment. Such breakthrough treatments and their stratospheric price tags have “absolutely” caused insurers to reconsider covering high-priced hepatitis, diabetes and other treatments, said Sumit Dutta, chief medical officer of Catamaran, the fourth-biggest U.S. pharmacy benefit manager, or PBM.
27 January 2014 | Bloomberg
The first study of hepatitis C infection among different Hispanic groups in the U.S. has found that infection with the virus varies widely, with Puerto Rican Hispanics much more likely than other groups to be infected.
14 January 2014 | Medical Xpress
Gilead Sciences (GILD) received approval earlier this month for what may well be one of the most successful drugs to be approved in years-- Sovaldi, its novel hepatitis drug. Sovaldi, which some analysts say can actually cure some hepatitis cases, is expected to be a blockbuster for the company and could see sales surpassing $8 billion annually by 2018. On the heels of the approval, Gilead announced that it will now seek U.S. approval for a combination of Sovaldi and its newest hepatitis drug -- ledipasvir -- in the first quarter of 2014. The combination of these two drugs could be a "one-two knockout"… not just of the disease, but of the competition as well.
03 January 2014 | Seeking Alpha
HIV positive men with higher hepatitis C virus (HCV) RNA levels in their blood during acute infection were more likely to have HCV in their semen as well, which may raise the risk of sexual transmission, researchers reported last month at the 64thAASLD Liver Meeting in Washington, DC.
20 December 2013 | HIVandHepatitis.com
The Ukraininan Community Advisory Board (UCAB) is the first-ever NGO, rather than a commercial organisation, to win an annual award in their country for the most successful PR stunt of the year. During the Action, aimed at shaming the Ukraininan government into providing better access to hepatitis C treatment, a hundred of “condemned” people lined up in front of the Government building with the cotton bags on their heads and ropes tied around their necks.
28 November 2013 | Ukrainian Community Advosory Board
Sofosbuvir is the first representative of a new class of antivirals that act as inhibitors of an essential enzyme of HCV, the NS5B ribonucleic acid polymerase. This medicine provides the first interferon-free treatment option for chronic hepatitis C.
22 November 2013 | European Medicines Agency